OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board
OS Therapies (NYSE American: OSTX) has appointed Borys Shor, PhD to its Antibody Drug Conjugate (ADC) Advisory Board. Dr. Shor will assist in selecting antibodies and payloads for the company's tunable ADC platform, which uses proprietary pH-sensitive SiLinker™ silicone linker technology. With 20 years of experience in oncology discovery programs, Dr. Shor brings expertise from roles at Pfizer, Wyeth, and as CEO of Manhattan BioSolutions. His background includes developing small molecule kinase inhibitors, biologics, and nanoparticles. At Pfizer, he led teams developing novel ADCs and supported the BLA filing for Inotuzumab, approved for leukemia treatment in 2017. Dr. Shor's appointment aims to strengthen OS Therapies' ADC development capabilities.
OS Therapies (NYSE American: OSTX) ha nominato Borys Shor, PhD nel suo Comitato Consultivo per gli Antibody Drug Conjugates (ADC). Il Dr. Shor assisterà nella selezione di anticorpi e payload per la piattaforma ADC modulabile dell'azienda, che utilizza la tecnologia brevettata del linker silicone sensibile al pH SiLinker™. Con 20 anni di esperienza nei programmi di scoperta in oncologia, il Dr. Shor porta con sé competenze acquisite in ruoli presso Pfizer, Wyeth e come CEO di Manhattan BioSolutions. La sua esperienza include lo sviluppo di inibitori chinasici a piccole molecole, biologici e nanoparticelle. Presso Pfizer, ha guidato team nello sviluppo di nuovi ADC e ha supportato la richiesta di BLA per Inotuzumab, approvato per il trattamento della leucemia nel 2017. La nomina del Dr. Shor mira a rafforzare le capacità di sviluppo ADC di OS Therapies.
OS Therapies (NYSE American: OSTX) ha nombrado a Borys Shor, PhD para su Consejo Asesor de Antibody Drug Conjugates (ADC). El Dr. Shor ayudará en la selección de anticuerpos y cargas para la plataforma ADC ajustable de la compañía, que utiliza la tecnología de enlace de silicona SiLinker™ sensible al pH. Con 20 años de experiencia en programas de descubrimiento oncológico, el Dr. Shor aporta experiencia de roles en Pfizer, Wyeth y como CEO de Manhattan BioSolutions. Su trayectoria incluye el desarrollo de inhibidores de quinasa de pequeñas moléculas, biológicos y nanopartículas. En Pfizer, lideró equipos que desarrollaron nuevos ADC y apoyó la presentación del BLA para Inotuzumab, aprobado para el tratamiento de la leucemia en 2017. La incorporación del Dr. Shor tiene como objetivo fortalecer las capacidades de desarrollo de ADC de OS Therapies.
OS Therapies (NYSE American: OSTX)는 Borys Shor, PhD를 항체 약물 접합체(ADC) 자문위원회에 임명했습니다. Shor 박사는 pH 민감성 SiLinker™ 실리콘 연결 기술을 사용하는 회사의 조정 가능한 ADC 플랫폼을 위한 항체 및 페이로드 선택을 지원합니다. 20년의 경험을 보유한 Shor 박사는 Pfizer, Wyeth에서의 역할 및 Manhattan BioSolutions의 CEO로서 얻은 전문성을 가지고 있습니다. 그의 배경에는 소분자 키나제 억제제, 생물학적 제제 및 나노입자 개발이 포함됩니다. Pfizer에서는 새로운 ADC 개발 팀을 이끌었고 2017년에 백혈병 치료를 위해 승인된 Inotuzumab의 BLA 제출을 지원했습니다. Shor 박사의 임명은 OS Therapies의 ADC 개발 역량을 강화하기 위한 목적입니다.
OS Therapies (NYSE American: OSTX) a nommé Borys Shor, PhD à son Conseil Consultatif sur les Antibody Drug Conjugates (ADC). Le Dr Shor aidera à la sélection des anticorps et des charges pour la plateforme ADC réglable de l'entreprise, qui utilise la technologie de lien en silicone SiLinker™ sensible au pH. Fort de 20 ans d'expérience dans les programmes de découverte en oncologie, le Dr Shor apporte son expertise acquise lors de ses postes chez Pfizer, Wyeth et en tant que PDG de Manhattan BioSolutions. Son parcours comprend le développement d'inhibiteurs de kinases de petites molécules, de biologiques et de nanoparticules. Chez Pfizer, il a dirigé des équipes développant de nouveaux ADC et a soutenu la demande de BLA pour Inotuzumab, approuvé pour le traitement de la leucémie en 2017. La nomination du Dr Shor vise à renforcer les capacités de développement d'ADC d'OS Therapies.
OS Therapies (NYSE American: OSTX) hat Borys Shor, PhD in seinen beratenden Ausschuss für Antibody Drug Conjugates (ADC) berufen. Dr. Shor wird bei der Auswahl von Antikörpern und Payloads für die modulare ADC-Plattform des Unternehmens unterstützen, die die proprietäre pH-sensible SiLinker™ Silikon-Verbindungstechnologie nutzt. Mit 20 Jahren Erfahrung in der Onkologie-Entwicklung bringt Dr. Shor Fachwissen aus Rollen bei Pfizer, Wyeth und als CEO von Manhattan BioSolutions mit. Sein Hintergrund umfasst die Entwicklung von kleinen Molekülinhibitoren für Kinasen, biologischen Medikamenten und Nanopartikeln. Bei Pfizer leitete er Teams zur Entwicklung neuartiger ADCs und unterstützte die BLA-Einreichung für Inotuzumab, das 2017 zur Behandlung von Leukämie zugelassen wurde. Die Berufung von Dr. Shor zielt darauf ab, die ADC-Entwicklungskompetenzen von OS Therapies zu stärken.
- Appointment of experienced oncology researcher Dr. Borys Shor to ADC Advisory Board
- Dr. Shor's expertise in ADC development, including work on FDA-approved Inotuzumab
- Potential enhancement of OS Therapies' ADC platform development capabilities
- None.
Dr. Shor has 20 years of experience in leading oncology discovery programs and external R&D partnerships at large pharma (Pfizer, Wyeth) and biotech companies, with specific focus on preclinical discovery and development of small molecule kinase inhibitors, biologics and nanoparticles. He is a founder and the CEO of Manhattan BioSolutions Inc. Dr. Shor also serves as a BioEntrepreneur-In-Residence with the Long Island Bioscience Hub and is a founder of BioIDEA, a biotech pitching forum in
He currently serves on the executive management team of early-stage biotech companies and is a life sciences investment advisor for a biotech hedge fund. Dr. Shor earned MS degree in molecular genetics from the St. Petersburg State University. He also received a PhD in Molecular and Cell Biology at the SUNY Downstate Medical Center and performed a postdoctoral fellowship in the Inflammation Research team at Johnson & Johnson Pharmaceutical R&D prior to joining Wyeth.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing strong preclinical efficacy data in various models of breast cancer. In addition, OS Therapies is advancing its next generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company’s proprietary silicone linker technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240822112221/en/
Corporate and Media Contact:
Jack Doll
410-297-7793
irpr@ostherapies.com
Investor Relations:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
OSTX@redchip.com
Source: OS Therapies
FAQ
Who is Borys Shor and what is his new role at OS Therapies (OSTX)?
What is OS Therapies' (OSTX) proprietary technology for ADC development?
What significant achievement did Dr. Shor contribute to at Pfizer?
How might Dr. Shor's appointment impact OS Therapies' (OSTX) ADC development?
